DRG Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast cancer for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s breast cancer forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with breast cancer each year?
  • Of all people diagnosed with breast cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of breast cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Note: Coverage may vary by country.

Table of contents

  • Breast Cancer - Epidemiology - Asia Pacific Data
    • Introduction
      • Key Findings
        • Key Updates
        • Incidence of Breast Cancer per 100,000 Women of All Ages in 2018 and 2028
        • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Breast Cancer over the Next Ten Years
        • Diagnosed Incident Cases of Breast Cancer in 2018 by Stage at Diagnosis
        • Number of Additional Incident Cases of Breast Cancer Incurred over the 2018-2028 Forecast Period in the Countries Under Study
    • Epidemiology Data
    • Methods
      • Lifetime DALYs Gained
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Molecular Subtype
      • Recurrent Incidence
      • Diagnosed Prevalence
      • Drug-Treatable Populations
    • Reference Materials
      • Literature Review
        • Risk/Protective Factors
          • Bibliography

      Author(s): Alexandre Vo Dupuy (PhamD, MSc)

      Alexandre joined Decision Resources Group in 2017 as an Associate Epidemiologist. He holds a PharmD from Paris Descartes University as well as a Master in pharmacoepidemiology from the University of Bordeaux. 

      Prior to joining Decision Resources Group, he worked within the fields of Consulting and Real World Evidence, and as an intern within the Global Epidemiology department of one of the top pharmaceutical company. As an associate epidemiologist, Alexandre works across multiple disease areas estimating and forecasting incidence and prevalence, with a focus on cancer epidemiology.

      Related Reports

      Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

      Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the meta...

      View Details

      Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast

      The breast cancer therapy market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s...

      View Details

      Breast Cancer | Disease Landscape and Forecast | G7 | 2020

      The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verze...

      View Details

      Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

      Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

      View Details